{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.6","upperLimit":"21.2","value":"19.4"},{"groupId":"OG001","lowerLimit":"4.83","upperLimit":"5.31","value":"5.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"Non-inducible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"20.8","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Inducible"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received Trametinib 1 mg or 2 mg tablets QD.","id":"OG001","title":"Part C: Trametinib"}],"paramType":"MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48","title":"Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib","type":"SECONDARY","unitOfMeasure":"Liters per hour (L/hr)"}